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Abstract
Background: The Int7G24A variant of transforming growth factor-beta receptor type I (TGFBR1)
has been shown to increase the risk for kidney, ovarian, bladder, lung and breast cancers. Its role
in colorectal cancer (CRC) has not been established. The aims of this study were to assess the
association of TGFBR1*Int7G24A variant with CRC occurrence, patient age, gender, tumour
location and stage.
Methods: We performed a case-control study with 504 cases of sporadic CRC; and 504 non-
cancerous age, gender and ethnically matched controls. Genotyping analysis was performed using
allelic discrimination assay by real time PCR.
Results: The Int7G24A variant was associated with increased CRC incidence in an additive model
of inheritance (P for trend = 0.005). No significant differences were found between Int7G24A
genotypes and tumour location or stage. Interestingly, the association of the Int7G24A variant with
CRC risk was significant in men (odds ratio 4.10 with 95% confidence intervals 1.41-11.85 for
homozygous individuals; P for trend = 0.00023), but not in women. We also observed an increase
in susceptibility to CRC for individuals aged less than 70 years.
Conclusion: Our data suggest that the Int7G24A variant represents a risk factor for CRC in the
male Spanish population.
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Transforming growth factor beta (TGF-β) is one of the
most potent inhibitors of proliferation in epithelial, neu-
ronal and hematopoietic cells. The effects of an activated
TGF-β signalling pathway include inhibition of cell cycle
progression, promotion of terminal differentiation and
activation of cell death [1].
TGF-β receptor type I (encoded by TGFBR1) is a mediator
of TGF-β growth inhibitory signals. Extracellular TGF-β
binds first to the type II receptor, which then dimerizes
and activates the type I receptor, sending the signal to the
nucleus via SMAD proteins [1]. Abnormalities of this sig-
nalling pathway are almost universal in cancer cells
through a variety of mechanisms [2]. Among them are
overexpression of the ligands, downregulation of recep-
tors, and point mutations and deletions in the genes cod-
ing for proteins involved in the pathway [3]. Different
TGFBR1 allelic variants have been associated with suscep-
tibility to develop different types of tumours. Thus, the
TGFBR1*6A allele, located at exon 1 (rs11466445) has
been shown to be a susceptibility allele for colorectal can-
cer (CRC), breast and ovarian cancers, based on a meta-
analysis of many case-control studies [4]. In contrast, one
recent report found a lack of an association between this
variant and CRC risk [5,6]. The role of this variant in CRC
susceptibility remains controversial.
The TGFBR1_Int7G24A polymorphism (rs334354;
NM_004612.2:c.1255+24G>A) has also been associated
with cancer risk, but the function of this variant has yet to
be discovered. Individuals carrying the Int7G24A variant
have an increased risk of developing non-small cell lung
cancer, renal cell carcinomas, transitional cell carcinomas
of the bladder, and breast cancer [7-10]. To our knowl-
edge, there is only one published report on the association
between this genetic variant and CRC [11]. In that study,
there was no evidence of an association between this pol-
ymorphism and colorectal cancer risk in familial cases.
To test whether the Int7G24A variant might be associated
with the incidence of CRC in the Spanish population, we
carried out a case-control study with 504 cases and 504
matched controls for age, gender and ethnicity. We found
a significant association of the Int7G24A variant with the
incidence of CRC. It also showed significant associations
with patient gender (male) and age, but not with tumour
location or stage. These data support the hypothesis that
Int7G24A variant may be a low penetrance tumour sus-
ceptibility allele that predisposes to CRC mainly in men in
the Spanish population.
Methods
Study subjects
A total of 504 sporadic cases of CRC and 504 controls
from the Elche University Hospital and Castellon Provin-
cial Hospital tissue banks were analysed in this study.
Written consent was obtained from every patient to be
included in the respective tissue banks. Patients diagnosed
with a familial cancer syndrome were excluded. Thus,
patients with Amsterdam II criteria for hereditary non-
polyposis colorectal cancer were excluded, as were
patients with Bethesda criteria and who were negative for
microsatellite instability, who were studied in our genetic
counselling unit.
This was a hospital-based case-control study. Controls
were selected from the same hospitals with no personal
history of cancer and selected according to diagnoses
unrelated to the disease of interest. They were matched for
age, gender and race/ethnicity with the study patients. The
study was approved by the Ethics Committees from the
Elche University and Castellon Provincial hospitals.
The median age for patients with CRC at diagnosis was 70
years (range 23-92); for controls it was 72 years (range 23-
98). Gender distribution for the patients with CRC
('cases') was 59.4% men and 40.6% women; for controls,
it was 53.3% and 46.7%, respectively. In 33.3% of the
cases, tumours were in the proximal colon and 66.7%
were located at the distal colon and rectum; 45% were
classified as low stage (I and II) and 55% as high stage (III
and IV). The numbers of cases and controls for whom
information was unavailable for stratification were 64 and
one, respectively.
DNA and RNA isolation and cDNA synthesis
Control DNA samples were obtained from peripheral
blood samples. DNA samples from cases were isolated
after mechanical homogenization of non-cancerous fro-
zen colorectal tissue. DNA isolation was performed using
an EZ1 BioRobot (Qiagen, Valencia, CA, USA) according
to the manufacturer's instructions. RNA was isolated from
normal colon tissue of selected cases in the same manner.
Synthesis of cDNA was performed using random primers
and Reverse Transcription reagents (Applied Biosystems,
Foster City, CA, USA).
Genotyping the Int7G24A polymorphism (rs334354)
A total of 1008 individuals (504 cases and 504 controls)
were analysed for this polymorphism. Single nucleotide
polymorphism (SNP) analysis was performed using a
real-time polymerase chain reaction (PCR) TaqMan assay
for allelic discrimination (TaqMan SNP Genotyping
Assay; ID: C_1413390_20; Applied Biosystems) with
minor modifications. All PCR reactions contained 20 ng
DNA, 10 μL TaqMan Universal Master Mix (Applied Bio-
systems), 0.5 μL of the assay and water for a final volume
of 20 μL. The appropriate negative controls were also run
in parallel. Real time PCR was performed on an ABI Prism
7300 Sequence Detection System (Applied Biosystems)
using the following conditions: 95°C for 10 min and 40Page 2 of 7
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min). Software in the system was used to quantify the flu-
orescent signals from VIC- or FAM-labelled probes. Two
representative cases for each genotype were sequenced
directly to confirm the genotyping results. Sequencing
reactions were performed using BigDye Terminator (ver-
sion 3.1) Cycle Sequencing kits and run in an ABI Prism
3100-Avant Genetic Analyser (Applied Biosystems).
Analysis of the lengths of Int7G24 and Int7A24 variant 
transcripts
Four cases previously genotyped as G/G and four geno-
typed as A/A were analysed to compare the length of their
TGFBR1 transcripts. This experiment was performed using
PCR and capillary electrophoresis. Primer sequences des-
ignated IVS7cDNA-F (labelled with 6-FAM) were 5'-
AAATTGCTCGACGATGTTCC-3' for exon 7, and
IVS7cDNA-R, 5'-CTCTGCCATCTGTTTGGGAT-3' for exon
8. The expected size of a normal PCR product was 151 bp.
Twenty-five nanograms of DNA were used in a total PCR
reaction volume of 25 μL AmpliTaq Gold PCR Master Mix
2 × (Applied Biosystems) and 20 pmol of each primer.
After an initial 9 min at 95°C, PCR was run for 40 cycles
of 95°C for 20 s; 55°C for 20 s and 72°C for 20 s; fol-
lowed by 10 min final extension at 72°C. Diluted (1/10)
PCR products along with Genescan 500 ROX size stand-
ards in HiDi formamide (Applied Biosystems,) were
resolved by capillary electrophoresis (ABI 3100 Avant,
Applied Biosystems) using POP6 polymer. GeneScan
Software was used for the analysis of PCR fragment
lengths (Applied Biosystems).
Statistical analysis
We first examined the Hardy-Weinberg equilibrium of
allelic distribution separately for cases and controls and
then compared the allele frequencies between cases and
controls. We evaluated the association of Int7G24A geno-
types with CRC using multivariate unconditional logistic
regression models assuming dominant (A/A and G/A, ver-
sus G/G), additive (G/G and G/A, versus A/A) or recessive
(A/A, versus G/G and G/A) modes of inheritance, respec-
tively. In our basic models, we adjusted for age and gen-
der. We explored the potential effects of modification by
age in an analysis stratified by the cases' median age at
diagnosis (≤70 or >70 years). A χ2 test was used to evalu-
ate the differences in Int7G24A variant carrier frequencies
between tumour and control groups for the dominant and
the recessive models and to analyse any association
between the SNP and clinical and pathological factors.
Armitage's trend test was used to calculate P for trend in
the additive model of inheritance. All P values were two-
sided and P < 0.05 was considered significant. Results are
expressed as the odds ratio (OR) and 95% confidence
interval (CI).
Results
Int7G24A genotyping
Genotype distribution in the control and case populations
did not deviate significantly from that expected for a pop-
ulation in Hardy-Weinberg equilibrium (P > 0.2). Allelic
frequencies found in controls were 0.815 and 0.184 for
the Int7G24 and Int7A24 alleles, respectively. For the
patients with CRC, these frequencies were 0.764 and
0.236, respectively. Genotyping of the Int7G24A polymor-
phism is shown in Figure 1. The crude ORs assuming
dominant, additive and recessive models of inheritance
showed a significant increase of CRC risk for individuals
carrying the Int7G24A variant. The best-fit model of inher-
itance was the additive one (P for trend = 0.005). Uncon-
ditional logistic regression adjusted for age, considering
the median age for cases (70 y) as the threshold level,
showed a statistically significant association of the
Int7G24A variant with CRC susceptibility, for those indi-
viduals younger than 70 years (P for trend = 0.004). No
statistically significant association was found between this
polymorphism and individuals aged over 70 years (Table
1).
The results after gender adjustment were clear-cut, with no
CRC risk association found for women and a strong statis-
tically significant association for the presence of the
Int7G24A variant and CRC in men (P for trend =
0.00023). The ORs for heterozygous and homozygous
individuals for the Int7G24A variant were 1.74 (95% CI:
1.19-2.54) and 4.10 (95% CI: 1.41-11.85), respectively
(Table 1). No significant associations were found between
different genotypes and tumour location or stage.
Lengths of Int7G24 and Int7A24 transcripts
We performed mRNA analysis from homozygous G/G and
A/A individuals to test if the Int7G24A variant might be
related to an abnormal mRNA splicing that could explain
the function of this allele as a risk factor for CRC. How-
ever, the mRNA fragments obtained always had the
expected size for normal mRNA splicing independently of
the genotype.
Discussion
The TGFβ pathway plays an important role in tumour
development and progression [1]. Recently, there has
been interest in the contribution of genetic variation in
this pathway to cancer susceptibility. Several polymorphic
variants in genes involved in this pathway have been stud-
ied [12]. The TGFBR1_Int7G24A variant has been previ-
ously associated with cancer risk, but the role of this
variant has yet to be discovered. Zhang et al [7] reported
that homozygous but not heterozygous carriers of this var-
iant have an increased risk of developing non-small cell
lung cancer. Chen et al [9] reported the association of thisPage 3 of 7
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2.2; 95% CI: 1.22-3.96) and transitional cell carcinoma of
the bladder (OR: 2.45; 95% CI: 1.8-3.16). In a meta-anal-
ysis of these three studies [8], the pooled OR was 1.76
(95% CI: 1.33-2.34; P < 0.0001). Another case-control
study [10] found an association with breast cancer (OR:
2.42; 95% CI: 1.55-3.79), suggesting that the Int7G24A
variant could also represent a risk factor for invasive and
metastatic breast cancers (OR: 2.61; 95% CI: 1.65-4.11).
Skoglund-Lundin et al. [11] did not detect a significant
association between CRC risk and the Int7G24A variant
when they analysed data from cases with a familial history
of colorectal cancer. The expectedly low-penetrance effect
of this putative susceptibility allele would be very difficult
to detect in cases with high-penetrance alleles. Moreover,
the authors did not stratify their data according to sex.
An exclusion criterion for the present study was the diag-
nosis of any familial cancer syndrome predisposing to
CRC, such as hereditary non-polyposis colorectal cancer,
familial adenomatous polyposis, Cowden disease and
Peutz-Jeghers syndrome. We were interested to evaluate
the effect of this SNP for sporadic CRC susceptibility and
tumour progression. The potential effect of the SNP on
familial syndromes as modifier of the penetrance, or the
phenotype expression should be approached independ-
ently in further specific studies.
Control individuals were selected from those patients
treated at an emergency department with diverse non-can-
cerous pathologies and with no personal history of cancer.
The probability that controls suffered from diseases puta-
tively caused by the same risk factors as the patients with
CRC is extremely low.
It is well known that one of the main limitations and
sources of confounding the results in association studies
comes from population stratification and inappropriate
sample sizes. A priori, our study with 504 sporadic cases
and 504 controls allowed us to detect an OR of 1.5 for G/
A heterozygous individuals (considering a frequency of
0.3) and an OR of 2.0 for A/A homozygous individuals
(considering a frequency of 0.025) with 80% power (two-
sided test, alpha level 5%). Estimated genotype frequen-
Genotyping of the Int7G24G>A polymorphismFigure 1
Genotyping of the Int7G24G>A polymorphism. (A) Real-time PCR for allelic discrimination. (B) Direct sequencing to 
confirm the genotypes.
A/AG/G G/A
B
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control population and were similar to the frequencies
registered at the SNP database for European populations
http://www.ncbi.nlm.nih.gov/projects/SNP/. The results
presented here show an increase of CRC susceptibility for
those individuals carrying the Int7G24A variant allele with
a dosage effect (additive model of inheritance). Adjusting
the OR by age, we only observed an association of
Int7G24A variant carriers with CRC risk in subjects aged
less than 70 years (Table 1). Thus, the genetic risk effect is
more evident in younger individuals. Ageing implies a
huge amount of acquired predisposing carcinogenic fac-
tors that could overshadow the mild effect of the suscepti-
bility alleles.
When we analysed the data adjusting by gender, we found
that the Int7G24A variant was strongly associated with
CRC risk in men but not women. We do not know why.
Evidence is accumulating supporting gender-related dif-
ferences in the development of CRC, but to our knowl-
edge, few reports have been published regarding sex-
specific relationship between SNPs and CRC. Slattery et al
[13] reported that the oestrogen receptor beta CA repeat
polymorphism was associated with an increase relative
risk of colon cancer in women but not in men. On the
contrary, increasing number of CAG repeats in the andro-
gen receptor was directly associated with colon cancer
among men, but not in women. Both oestrogen and
androgen receptors are present in colorectal tissue and it
has been suggested that these might be important in regu-
lating the CRC risk associated with these hormones. Acti-
vation of the TGFβ signal transduction system is also
subject to hormonal regulation [14]. This striking connec-
tion might suggest the involvement of sex steroid hor-
Table 1: Genotypes of the Int7G24A polymorphism in cases and controls and their association with CRC.
Int7G24A genotype Cases
(n = 504)
Controls
(n = 504)
OR [95% CI] p
Dominant model number (%) number (%)
G/G 296 (58.73) 333 (66.07) 1 (ref)
G/A and A/A 208 (41.27) 171 (33.93) 1.37 [1.06-1.77] 0.019*
Additive model
G/G 296 (58.73) 333 (66.07) 1 (ref)
G/A 178(35.32) 156 (30.95) 1.28 [0.98-1.67]
A/A 30 (5.95) 15 (2.98) 2.25 [1.20-4.23] 0.005**
Recessive model
G/G and G/A 474 (94.05) 489 (97.02) 1 (ref)
A/A 30 (5.95) 15 (2.98) 2.04 [1.11-3.85] 0.032*
≤ 70 yrs
(n = 213)
≤ 70 yrs
(n = 219)
G/G, number (%) 118 (55.40) 150 (68.49) 1 (ref)
G/A, number (%) 80 (37.56) 61 (27.85) 1.67 [1.11-2.51]
A/A, number (%) 15 (7.04) 8 (3.65) 2.38 [1.00-5.68] 0.004**
>70 yrs
(n = 227)
>70 yrs
(n = 284)
G/G, number (%) 145 (63.88) 182 (64.08) 1 (ref)
G/A, number (%) 72 (31.72) 95 (33.45) 0.95 [0.65-1.39]
A/A, number (%) 10 (4.41) 7 (2.46) 1.79 [0.69-4.67] 0.662**
males
(n = 295)
males
(n = 226)
G/G, number (%) 166 (56.27) 160 (70.80) 1 (ref)
G/A, number (%) 112 (37.97) 62 (27.43) 1.74 [1.19-2.54]
A/A, number (%) 17 (5.76) 4 (1.77) 4.10 [1.41-11.85] 0.00023**
females
(n = 202)
females
(n = 277)
G/G, number (%) 126 (62.38) 172 (62.09) 1 (ref)
G/A, number (%) 63 (31.19) 94 (33.94) 0.92 [0.62-1.36]
A/A, number (%) 13 (6.44) 11 (3.97) 1.61 [0.71-3.65] 0.688**
* χ2 test; ** p for trend (Armitage's trend test)Page 5 of 7
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of CRC.
The apolipoprotein E (ApoE) epsilon 2/3 polymorphism
is another example of gender-specific modulation of CRC
risk and prognosis where men have a highly significant
association but there is no association in women [15]. Bae
et al [16] found a gender-specific association between pol-
ymorphisms of the gene for vascular endothelial growth
factor (VEGF 936 C>T) and CRC in the Korean popula-
tion. T allele-bearing genotypes significantly increased the
risk for CRC in women but not in men. Moreover, there
are gender-related survival differences in association with
EGFR (gene for epidermal growth factor receptor) poly-
morphisms in patients with metastatic colon cancers [17].
Again, oestrogens and androgens may be behind all these
associations because of their functional links with ApoE
[18], VEGF [19] and EGFR [20].
It is possible that the positive associations shown here
were not based on real effects of this polymorphism, but
rather reflect unknown differences in population ancestry
between the case and control groups [21]. We consider the
probability of false-positive inference attributable to pop-
ulation stratification to be small, because the cases and
control individuals were recruited from an ethnically
homogeneous population with no indication of a signifi-
cant amount of recent genetic admixture.
Given our results and those in the literature, it seems rea-
sonable to speculate that there might be a gender-depend-
ent allelic architecture for CRC risk associated with sex
steroids. This would introduce a new level of complexity
in the 'common disease-common variant' hypothesis
[22]. Our association studies between this polymorphism
and clinicopathological factors did not show any statisti-
cally significant results. The lack of difference in genotype
distribution between male and female patients with CRC
might be attributed to the contribution and compensa-
tion of other gender-related susceptibility polymor-
phisms, where the risks affect women preferentially. To
date, how this intronic SNP affects oncogenesis remains to
be elucidated. It has been proposed that this SNP creates
an alternative splice site within intron 7. In vitro analysis
with breast and ovarian cell lines from carriers of the
Int7G24A variant have shown the retention of the seventh
intron in the mRNA up to the site of the Int7G24A variant
[23]. We wanted to study if this alternative splicing also
occurred in the normal colorectal tissue from patients
with CRC. However, we concluded that factors other than
alternative splicing might account for the association of
this polymorphism with cancer, although we cannot rule
out the possibility that Int7G24A variant is a marker rep-
resenting a TGFBR1 haplotype. In this regard, it is interest-
ing to note the likely 'bystander susceptibility effect' for
the TGFBR1*6A allele because of linkage disequilibrium
with the unknown causative mutation of the allele-spe-
cific expression (ASE) in the TGFBR1 gene [24]. In our
series, no linkage disequilibrium was found between the
TGFBR1*6A and Int7G24A variant (unpublished results).
No information is available regarding the association
between variant and ASE. Further studies are required to
characterize the molecular mechanisms by which variant
is involved in gender-specific susceptibility to CRC.
Conclusion
The results of the present study strongly suggest that the
TGFBR1_Int7G24A allele does confer an increased risk of
colorectal cancer in the male Spanish population. The
growing list of gender-dependent association of allelic
variants and the risk of colorectal cancer might suggest the
involvement of sex steroid hormones in the aetiology of
CRC.
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